Board and Senior Leadership Changes

Summary by AI BETAClose X

Aptamer Group has strengthened its senior team by appointing Dr Paloma Giangrande as a Non-Executive Director and Dr James McNamara as Head of Oligonucleotide Therapeutic Development while Dr David Bunka steps down from the Board to focus on R&D; management says the AI/ML build was completed six months early, automation is integrated, lead candidate generation has started and the first in vivo Optimer-targeted radiotherapy study is underway with in vivo studies funded in March 2026, and Paloma’s prior programmes were acquired by Bristol Myers Squibb for US$1.5 billion; she holds no ordinary shares.

Disclaimer*

UK 100

Latest directors dealings